Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations-Genomic Features Associated with Response to Therapy.

Date publication

octobre 2025

Journal

European urology oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BARTHELEMY Philippe

Tous les auteurs :
Fizazi K, de Bono JS, Laird AD, Barthélémy P, Delva R, Dorff T, Maruzzo M, Stirling A, Machiels JP, Dumez H, Renard V, Hopkins JF, Albacker LA, Chen HC, Healy CG, DeAnnuntis L, Chelliserry J, van Oort IM, Scagliotti GV, Mehra N

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41173779

Résumé

The impact of alterations beyond DNA damage response-homologous recombination repair (DDR-HRR) genes on outcomes with poly(ADP-ribose) polymerase inhibitor monotherapy remains unknown. This study aims to explore the impact of genomic features and co-occurring alterations on treatment outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) and DDR-HRR alterations in TALAPRO-1.

Mots clés

Genomic loss of heterozygosity, Homologous recombination repair, Metastatic castration-resistant prostate cancer, Talazoparib, Tumor mutational burden

Référence

Eur Urol Oncol. 2025 10 30;: